Medtronic Announces FDA Approval of InterStim Therapy for Bowel Control

Medtronic, Inc. MDT today announced U.S. Food and Drug Administration (FDA) approval of InterStim Therapy for Bowel Control. InterStim Therapy, previously available to treat the symptoms of overactive bladder and non-obstructive urinary retention, is now also approved for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments. InterStim Therapy for Bowel Control is a new, minimally invasive option proven to improve or restore bowel control in more than 80 percent of patients who received the therapy in a multi-center clinical trial.